Health care partner Tom Bulleit (Washington, D.C.) addressed the U.S. Food & Drug Administration’s bid to lower drug prices in a July 18 article published in The Washington Post that was reprinted in The San Francisco Chronicle and Connecticut Post.
Mr. Bulleit expressed skepticism that policy actions suggested so far by FDA, which has no official role in how drug prices are set, would result in significant decreases in list prices for prescription drugs, or the out-of-pocket costs of any substantial number of health care consumers.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find our more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.